Myrto T. Samara

Prof. Myrto T. Samara

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

18 August 2020 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
AVAndreas Vadarlis
Andreas Vadarlis
CAChristina Antza
Christina Antza
DBDimitra Rafailia Bakaloudi
Dimitra Rafailia Bakaloudi
IDIoannis Doundoulakis
Ioannis Doundoulakis
GKGeorgios Kalopitas
Georgios Kalopitas
MCMichael Chourdakis
Michael Chourdakis

14 April 2015 in BMC Medicine
Verified
Journal Article
Open access
PDF file
BHBartosz Helfer
Bartosz Helfer
APAaron Prosser
Aaron Prosser
MSMyrto T. Samara
Myrto T. Samara
JGJohn R Geddes
John R Geddes
ACAndrea Cipriani
Andrea Cipriani
SLStefan Leucht
Stefan Leucht
As the number of systematic reviews is growing rapidly, we systematically investigate whether meta-analyses published in leading medical journals present an outline of available evidence by referring to previous meta-analyses and systematic reviews. We searched PubMed for recent meta-analyses of pharmacological treatments published in high impact factor journals. Previous systematic reviews and meta-analyses were identified with electronic searches of keywords and by searching reference sections. We analyzed the number of meta-analyses and systematic reviews that were cited, described and discussed in each recent meta-analysis. Moreover, we investigated publication characteristics that potentially influence the referencing practices. We identified 52 recent meta-analyses and 242 previous meta-analyses on the same topics. Of these, 66% of identified previous meta-analyses were cited, 36% described, and only 20% discussed by recent meta-analyses. The probability of citing a previous meta-analysis was positively associated with its publication in a journal with a higher impact factor (odds ratio, 1.49; 95% confidence interval, 1.06 to 2.10) and more recent publication year (odds ratio, 1.19; 95% confidence interval 1.03 to 1.37). Additionally, the probability of a previous study being described by the recent meta-analysis was inversely associated with the concordance of results (odds ratio, 0.38; 95% confidence interval, 0.17 to 0.88), and the probability of being discussed was increased for previous studies that employed meta-analytic methods (odds ratio, 32.36; 95% confidence interval, 2.00 to 522.85). Meta-analyses on pharmacological treatments do not consistently refer to and discuss findings of previous meta-analyses on the same topic. Such neglect can lead to research waste and be confusing for readers. Journals should make the discussion of related meta-analyses mandatory.

10 June 2020 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Open access
PDF file
MSMyrto T. Samara
Myrto T. Samara
MHM. Huhn
M. Huhn
VCV. Chiocchia
V. Chiocchia
JSJ. Schneider‐Thoma
J. Schneider‐Thoma
MWM. Wiegand
M. Wiegand
SLS. Leucht
S. Leucht
Objectives: Symptoms of insomnia are highly prevalent in the elderly. A significant number of pharmacological and non‐pharmacological interventions exist, but, up‐to‐date, their comparative efficacy and safety has not been sufficiently assessed.Methods: We integrated the randomized evidence from every available treatment for insomnia in the elderly (>65 years) by performing a network meta‐analysis. Several electronic databases were searched up to May 25, 2019. The two primary outcomes were total sleep time and sleep quality. Data for other 6 efficacy and 8 safety outcomes were also analyzed.Results: Fifty‐three RCTs with 6832 participants (75 years old on average) were included, 43 of which examined the efficacy of one or more drugs. Ten RCTs examined the efficacy of non‐pharmacological interventions and were evaluated only with pairwise meta‐analyses because they were disconnected from the network. The overall confidence in the evidence was very low primarily due to the small amount of data per comparison and their sparse connectedness. Several benzodiazepines, antidepressants, and z‐drugs performed better in both primary outcomes, but few comparisons had data from more than one trial. The limited evidence on non‐pharmacological interventions suggested that acupressure, auricular acupuncture, mindfulness‐based stress reduction program, and tart cherry juice were better than their control interventions. Regarding safety, no clear differences were detected among interventions due to large uncertainty.Conclusions: Insufficient evidence exists on which intervention is more efficacious for elderly patients with insomnia. More RCTs, with longer duration, making more direct interventions among active treatments and presenting more outcomes are urgently needed.

1 November 2018 in Schizophrenia Research
Verified
Journal Article
Open access
SLStefan Leucht
Stefan Leucht
ACAnna Chaimani
Anna Chaimani
CLClaudia Leucht
Claudia Leucht
MHMaximilian Huhn
Maximilian Huhn
DMDimitris Mavridis
Dimitris Mavridis
JDJohn M Davis
John M Davis
A recent meta-regression had shown that the degree of placebo response, which has increased over the decades, is the major predictor of drug-placebo differences in antipsychotic drug trials in acutely ill patients with schizophrenia. Drug response, however, had remained stable. In the current meta-regression we explored the factors that are associated with placebo-response. We searched multiple electronic databases, ClinicalTrials.gov and the FDA website for randomized, placebo-controlled, antipsychotic drug trials in patients with acute exacerbations of schizophrenia. The outcome was the degree of placebo response measured by the BPRS or PANSS change from baseline to endpoint. 26 patient-, design-, and drug-related potential predictors of placebo response were analyzed by univariable and multivariable meta-regressions. 167 double-blind randomized controlled trials with 28,102 participants were included. The mean PANSS change from baseline was 6.25 (95% CI 4.64,7.85). More recent publication year, larger study sample size, more study sites, use of the PANSS rather than the BPRS scale to measure response, shorter wash-out phases, shorter study duration, lower mean age and shorter duration of illness were associated with larger placebo response in univariable analyses. In a multivariable analysis only the number of study participants and mean participant age had an impact on placebo response. The degree of placebo response is moderated by a number of design and patient-related factors. These explanatory variables of placebo response are only in part identical with those that moderated drug-placebo differences.

6 October 2020 in Evidence Based Mental Health
Verified
Journal Article
Closed access
PDF file
SLStephen Levine
Stephen Levine
KYKazufumi Yoshida
Kazufumi Yoshida
YGYair Goldberg
Yair Goldberg
MSMyrto T. Samara
Myrto T. Samara
ACAndrea Cipriani
Andrea Cipriani
TFToshi A Furukawa
Toshi A Furukawa
Background The Mini-Mental State Examination (MMSE), the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) and the Severe Impairment Battery (SIB) are widely used rating scales to assess cognition in Alzheimer’s disease. Objective To understand the correspondence between these rating scales, we aimed to examine the linkage of MMSE with the ADAS-Cog and SIB total and change scores. Methods We used individual-level data on participants with Alzheimer’s disease (n=2925) from five pivotal clinical trials of donepezil. Data were collected at baseline and scheduled visits for up to 6 months. We used equipercentile linking to identify the correspondence between simultaneous measurements of MMSE with ADAS-Cog, and SIB total and change ratings. Findings Spearman’s correlation coefficients were of strong magnitude between the MMSE total score and the ADAS-Cog (rs from −0.82 to −0.87; p<0.05) and SIB total scores (rs from 0.70 to 0.75; p<0.05). Weaker correlations between the change scores were observed between the MMSE change score and the ADAS-Cog (week 1: r=−0.11, p=0.18; rs thereafter: −0.28 to −0.45; p<0.05) and SIB change scores (rs from 0.31 to 0.44; p<0.05). Linking suggested that the MMSE total scores were sensitive to moderate and severe cognitive impairment levels. Despite weak to moderate correlations for the change scores, moderate change levels linked well, indicating ceiling and floor effects. Conclusions The current results can be used in meta-analyses, data harmonisation and may contribute to increasing statistical power when pooling data from multiple sources. Clinical implications The current study results help clinicians to understand these cognitive rating scale scores.